Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Associação Médica Brasileira (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500611 |
Resumo: | SUMMARY INTRODUCTION: Drug interaction is an important cause of global morbidity. It is of particular importance in cancer patients since they are often in use of polypharmacy, related to interactions between the drugs and the chemotherapeutics used. OBJECTIVE: To evaluate the drug interaction between chemotherapy and other drugs in cancer patients. METHODS: a cross-sectional study carried out in the outpatient oncology department of a public tertiary hospital. Two hundred thirty-five patients were included, and the drugs they were using were identified. Using the MedScape and Epocrates database, we evaluated the interactions between medications and chemotherapy by defining their frequency and dividing their severity from interaction into mild, close monitoring necessity and severe. RESULTS: 161 patients had some drug interaction. We identified 9 types of mild interactions, 23 types of interactions with close monitoring necessity, and 2 types of serious interactions. The most frequent interactions were between fluorouracil and leucovorin (32 cases) and cyclophosphamide and doxorubicin (19 cases). Serious interactions were between aspirin and pemetrexed; and leucovorin and Bactrim. CONCLUSION: In the present study, drug interactions were frequent, including serious interactions with a potential increase in morbidity and mortality. Thus, it is necessary for oncologists to draw up a therapeutic plan considering potential interactions between prescribed chemotherapy and current medications in use by patients. |
id |
AMB-1_46158c7fd7c15dbd1cb2bebfbae17d3a |
---|---|
oai_identifier_str |
oai:scielo:S0104-42302019000500611 |
network_acronym_str |
AMB-1 |
network_name_str |
Revista da Associação Médica Brasileira (Online) |
repository_id_str |
|
spelling |
Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patientsDrug interactionsAntineoplastic agents/adverse effectsMedical oncologySUMMARY INTRODUCTION: Drug interaction is an important cause of global morbidity. It is of particular importance in cancer patients since they are often in use of polypharmacy, related to interactions between the drugs and the chemotherapeutics used. OBJECTIVE: To evaluate the drug interaction between chemotherapy and other drugs in cancer patients. METHODS: a cross-sectional study carried out in the outpatient oncology department of a public tertiary hospital. Two hundred thirty-five patients were included, and the drugs they were using were identified. Using the MedScape and Epocrates database, we evaluated the interactions between medications and chemotherapy by defining their frequency and dividing their severity from interaction into mild, close monitoring necessity and severe. RESULTS: 161 patients had some drug interaction. We identified 9 types of mild interactions, 23 types of interactions with close monitoring necessity, and 2 types of serious interactions. The most frequent interactions were between fluorouracil and leucovorin (32 cases) and cyclophosphamide and doxorubicin (19 cases). Serious interactions were between aspirin and pemetrexed; and leucovorin and Bactrim. CONCLUSION: In the present study, drug interactions were frequent, including serious interactions with a potential increase in morbidity and mortality. Thus, it is necessary for oncologists to draw up a therapeutic plan considering potential interactions between prescribed chemotherapy and current medications in use by patients.Associação Médica Brasileira2019-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500611Revista da Associação Médica Brasileira v.65 n.5 2019reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.65.5.611info:eu-repo/semantics/openAccessMonteiro,Camila Ribeiro de ArrudaSchoueri,Jean Henri MaselliCardial,Debora TerraLinhares,Lívia de CastroTurke,Karine CorcioneSteuer,Lia VineyardMenezes,Levy Werneck de AlmeidaArgani,Igor LuizSette,ClaudiaCubero,Daniel de Iracema GomesGiglio,Auro deleng2019-05-28T00:00:00Zoai:scielo:S0104-42302019000500611Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2019-05-28T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false |
dc.title.none.fl_str_mv |
Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients |
title |
Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients |
spellingShingle |
Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients Monteiro,Camila Ribeiro de Arruda Drug interactions Antineoplastic agents/adverse effects Medical oncology |
title_short |
Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients |
title_full |
Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients |
title_fullStr |
Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients |
title_full_unstemmed |
Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients |
title_sort |
Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients |
author |
Monteiro,Camila Ribeiro de Arruda |
author_facet |
Monteiro,Camila Ribeiro de Arruda Schoueri,Jean Henri Maselli Cardial,Debora Terra Linhares,Lívia de Castro Turke,Karine Corcione Steuer,Lia Vineyard Menezes,Levy Werneck de Almeida Argani,Igor Luiz Sette,Claudia Cubero,Daniel de Iracema Gomes Giglio,Auro del |
author_role |
author |
author2 |
Schoueri,Jean Henri Maselli Cardial,Debora Terra Linhares,Lívia de Castro Turke,Karine Corcione Steuer,Lia Vineyard Menezes,Levy Werneck de Almeida Argani,Igor Luiz Sette,Claudia Cubero,Daniel de Iracema Gomes Giglio,Auro del |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Monteiro,Camila Ribeiro de Arruda Schoueri,Jean Henri Maselli Cardial,Debora Terra Linhares,Lívia de Castro Turke,Karine Corcione Steuer,Lia Vineyard Menezes,Levy Werneck de Almeida Argani,Igor Luiz Sette,Claudia Cubero,Daniel de Iracema Gomes Giglio,Auro del |
dc.subject.por.fl_str_mv |
Drug interactions Antineoplastic agents/adverse effects Medical oncology |
topic |
Drug interactions Antineoplastic agents/adverse effects Medical oncology |
description |
SUMMARY INTRODUCTION: Drug interaction is an important cause of global morbidity. It is of particular importance in cancer patients since they are often in use of polypharmacy, related to interactions between the drugs and the chemotherapeutics used. OBJECTIVE: To evaluate the drug interaction between chemotherapy and other drugs in cancer patients. METHODS: a cross-sectional study carried out in the outpatient oncology department of a public tertiary hospital. Two hundred thirty-five patients were included, and the drugs they were using were identified. Using the MedScape and Epocrates database, we evaluated the interactions between medications and chemotherapy by defining their frequency and dividing their severity from interaction into mild, close monitoring necessity and severe. RESULTS: 161 patients had some drug interaction. We identified 9 types of mild interactions, 23 types of interactions with close monitoring necessity, and 2 types of serious interactions. The most frequent interactions were between fluorouracil and leucovorin (32 cases) and cyclophosphamide and doxorubicin (19 cases). Serious interactions were between aspirin and pemetrexed; and leucovorin and Bactrim. CONCLUSION: In the present study, drug interactions were frequent, including serious interactions with a potential increase in morbidity and mortality. Thus, it is necessary for oncologists to draw up a therapeutic plan considering potential interactions between prescribed chemotherapy and current medications in use by patients. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-05-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500611 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500611 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1806-9282.65.5.611 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Revista da Associação Médica Brasileira v.65 n.5 2019 reponame:Revista da Associação Médica Brasileira (Online) instname:Associação Médica Brasileira (AMB) instacron:AMB |
instname_str |
Associação Médica Brasileira (AMB) |
instacron_str |
AMB |
institution |
AMB |
reponame_str |
Revista da Associação Médica Brasileira (Online) |
collection |
Revista da Associação Médica Brasileira (Online) |
repository.name.fl_str_mv |
Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB) |
repository.mail.fl_str_mv |
||ramb@amb.org.br |
_version_ |
1754212834186625024 |